Publication Topic

Chang X, Kleinstreuer N, Ceger P, Choksi N, Hseih J-H, Wetmore BA et al. In vitro to in vivo extrapolation for estrogenic activity of environmental chemicals. Poster presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Unice KM, Kerger BD, Paustenbach DJ, Finley BL, Tvermoes BE. 2014. Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. Chem-Biol Interact 216:53–74; doi: 10.1016/j.cbi.2014.04.001. PMID: 24726710.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

Sterner TR, Ruark CD, Covington TR, Yu KO, Gearhart JM. 2013. A physiologically based pharmacokinetic model for theoxime TMB-4: Simulation of rodent and human data. Arch Toxicol 87:661–680; doi: 10.1007/s00204-012-0987-z.

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016.

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Fowler, JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. 2012. Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane 5 serine mutations. Mol Pharmacol 81(6):820-831; doi: 10.1124/mol.111.075457. PMID: 22416052.

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278; doi: 10.2133/dmpk.DMPK-11-SC-114.

Hart BR, Mishra PK, Lintner RE, Hinerman JM, Herr AB, Blumenthal RM. 2011. Recognition of DNA by the helix-turn-helix global regulatory protein Lrp is modulated by the amino terminus. J Bacteriol 193(15):3794–3803; doi: 10.1128/jb.00191-11. PMID: 21642464.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.

Covington T, Jakubowski E, McGuire J, Byers C, Evans R, Hulet S, Whalley C, Lumley L, Clarkson E, Gearhart J. A multi-species and -route, ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Poster presented at the Bioscience Review Conference, Baltimore, MD, May 2010.

Yu KO, Ruark CD, Hack CE, Sterner TR, Covington TR, Gearhart JM. A physiologically based pharmacokinetic model for pralidoxime in the guinea pig and human. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2010.

Yu K, Covington T, Ruark C, Sterner T, Hack E, Gearhart J. A physiologically based pharmacokinetic model for pralidoxime in the guinea pig and in human. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Covington TR, Jakubowski EM, McGuire JM, Byers CE, Evans RA, Hulet SW, et al. A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

Covington TR, Gearhart JM, Jakubowski EM, McGuire JM, Evans RA, Hulet SW. Physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling of VX exposure through various routes to multiple species. Poster presented at the Chemical and Biological Defense Physical Science and Technology Conference, New Orleans, LA, November 2008.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.